{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:55Z","timestamp":1788502375926,"version":"build-2803163510"},"reference-count":24,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shandong Second Medical University Affiliated Hospital Scientific Research Development Fund Project","award":["2025FYM045"],"award-info":[{"award-number":["2025FYM045"]}]},{"name":"Weifang Municipal Health Commission Scientific Research Project","award":["WFWSJK-2022-133"],"award-info":[{"award-number":["WFWSJK-2022-133"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Healthcare settings are high-risk environments for the transmission of respiratory viruses. Effective strategies to prevent hospital-acquired influenza, particularly post-exposure prophylaxis for close contacts (CCs), are urgently needed. This study aims to assess the effectiveness of baloxavir marboxil (baloxavir) and oseltamivir in preventing influenza virus infection among CCs who have been exposed to confirmed influenza cases and are unable to be immediately isolated in the hospital ward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This multicentre, randomised, open-label, parallel-controlled trial involves hospitalised patients with laboratory-confirmed influenza (index patients) and their CCs. CCs will be randomised into three groups: baloxavir marboxil, oseltamivir or placebo. Baloxavir (40 mg or 80 mg for \u226580\u2009kg) will be administered as a single dose on day 1, while oseltamivir (75 mg) will be given once a day for 5 days. CCs will be monitored for influenza-like symptoms, with respiratory samples collected for rapid antigen test or reverse-transcription PCR testing at baseline, day 5\u00b11 and day 10\u00b11 or earlier if symptoms develop. The primary outcome is the 5-day incidence of clinical influenza, defined as laboratory-confirmed infection with concurrent fever and at least one respiratory symptom. Secondary outcomes will include the 5-day incidence of laboratory-confirmed influenza, the 10-day incidence of clinical influenza and the percentage of CCs infected with resistance-associated treatment-emergent influenza variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has been approved by the Clinical Research Ethics Committee of China-Japan Friendship Hospital (2024-KY-401). The results of the study will be submitted for publication in a peer-reviewed journal with online accessibility. The full protocol, de-identified participant data and statistical code will be openly available in a public repository within 12 months after trial completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06762587\">NCT06762587<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118748","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:00:45Z","timestamp":1787227245000},"page":"e118748","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A randomised, open-label clinical study on the efficacy of baloxavir marboxil and oseltamivir for post-exposure prevention of influenza in a hospital setting: a study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06762587","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0546-6025","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Chu","sequence":"additional","affiliation":[{"name":"China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"},{"name":"National Center for Respiratory Medicine, Beijing, China"},{"name":"State Key Laboratory of Respiratory Health and Multimorbidity, Beijing, China"},{"name":"National Clinical Research Center for Respiratory Diseases, Beijing, China"},{"name":"Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8881-5242","authenticated-orcid":false,"given":"Lijie","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5449-669X","authenticated-orcid":false,"given":"Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Center, Weifang People\u2019s Hospital, Shandong Second Medical University, Weifang, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026090322303123000_16.8.e118748.1","article-title":"Seasonal Influenza: A Narrative Review of Epidemiology, Clinical Features, and Preventive Strategies","volume":"17","author":"Kyokha Ameen","year":"2025","journal-title":"Cureus"},{"key":"2026090322303123000_16.8.e118748.2","unstructured":"Centers for Disease Control and Prevention . About pandemic influenza. Available: https:\/\/www.cdc.gov\/pandemic-flu\/basics\/index.html [Accessed 27 Mar 2024]."},{"key":"2026090322303123000_16.8.e118748.3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/irv.12080","article-title":"Routes of influenza transmission","volume":"7 Suppl 2","author":"Killingley","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"2026090322303123000_16.8.e118748.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00535-6"},{"key":"2026090322303123000_16.8.e118748.5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025142","article-title":"The epidemiological and clinical characteristics of the hospital-acquired influenza infections","volume":"100","author":"Li","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026090322303123000_16.8.e118748.6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ajic.2017.04.008","article-title":"Working with influenza-like illness: Presenteeism among US health care personnel during the 2014-2015 influenza season","volume":"45","author":"Chiu","year":"2017","journal-title":"Am J Infect Control"},{"key":"2026090322303123000_16.8.e118748.7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial","volume":"355","author":"Nicholson","year":"2000","journal-title":"The Lancet"},{"key":"2026090322303123000_16.8.e118748.8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(19)32982-4","article-title":"Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial","volume":"395","author":"Butler","year":"2020","journal-title":"The Lancet"},{"key":"2026090322303123000_16.8.e118748.9","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019826565"},{"key":"2026090322303123000_16.8.e118748.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"2026090322303123000_16.8.e118748.11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026090322303123000_16.8.e118748.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915341"},{"key":"2026090322303123000_16.8.e118748.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.748"},{"key":"2026090322303123000_16.8.e118748.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113633","article-title":"Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies","volume":"9","author":"Okoli","year":"2014","journal-title":"PLoS One"},{"key":"2026090322303123000_16.8.e118748.15","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13243","article-title":"Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study","volume":"18","author":"Maurel","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2026090322303123000_16.8.e118748.16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhin.2016.05.012","article-title":"Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards","volume":"94","author":"Ishiguro","year":"2016","journal-title":"J Hosp Infect"},{"key":"2026090322303123000_16.8.e118748.17","doi-asserted-by":"publisher","DOI":"10.1086\/381128"},{"key":"2026090322303123000_16.8.e118748.18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa240","article-title":"Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study","volume":"7","author":"Lepen","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026090322303123000_16.8.e118748.19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1248\/bpb.b21-00165","article-title":"Assessment of Adherence to Post-exposure Prophylaxis with Oseltamivir in Healthcare Workers: A Retrospective Questionnaire-Based Study","volume":"44","author":"Okada","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"2026090322303123000_16.8.e118748.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.008"},{"key":"2026090322303123000_16.8.e118748.21","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1093\/cid\/ciaa1622","article-title":"Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study","volume":"72","author":"Komeda","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026090322303123000_16.8.e118748.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci Rep"},{"key":"2026090322303123000_16.8.e118748.23","doi-asserted-by":"publisher","DOI":"10.1093\/INFDIS\/JIZ244"},{"key":"2026090322303123000_16.8.e118748.24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa061"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:30:54Z","timestamp":1788499854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-118748"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118748","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}